These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 9531302)

  • 1. A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway.
    Challita-Eid PM; Penichet ML; Shin SU; Poles T; Mosammaparast N; Mahmood K; Slamon DJ; Morrison SL; Rosenblatt JD
    J Immunol; 1998 Apr; 160(7):3419-26. PubMed ID: 9531302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A RANTES-antibody fusion protein retains antigen specificity and chemokine function.
    Challita-Eid PM; Abboud CN; Morrison SL; Penichet ML; Rosell KE; Poles T; Hilchey SP; Planelles V; Rosenblatt JD
    J Immunol; 1998 Oct; 161(7):3729-36. PubMed ID: 9759898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-1-HSA (CD80-CD24), a recombinant hybrid costimulatory molecule retains ligand binding and costimulatory functions.
    Wang YC; Sashidharamurthy R; Nagarajan S; Selvaraj P
    Immunol Lett; 2006 Jun; 105(2):185-92. PubMed ID: 16621031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
    Blanco B; Holliger P; Alvarez-Vallina L
    Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
    Rohrbach F; Gerstmayer B; Biburger M; Wels W
    Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell co-stimulation through B7RP-1 and ICOS.
    Yoshinaga SK; Whoriskey JS; Khare SD; Sarmiento U; Guo J; Horan T; Shih G; Zhang M; Coccia MA; Kohno T; Tafuri-Bladt A; Brankow D; Campbell P; Chang D; Chiu L; Dai T; Duncan G; Elliott GS; Hui A; McCabe SM; Scully S; Shahinian A; Shaklee CL; Van G; Mak TW; Senaldi G
    Nature; 1999 Dec; 402(6763):827-32. PubMed ID: 10617205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
    Liu A; Hu P; Khawli LA; Epstein AL
    Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
    Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
    J Immunol; 1997 May; 158(10):4584-90. PubMed ID: 9144470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
    Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
    Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity.
    Chakrabarti R; Zhou ZF; Chang Y; Prud'homme GJ
    Vaccine; 2005 Aug; 23(37):4553-64. PubMed ID: 15919138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.
    Chapoval AI; Ni J; Lau JS; Wilcox RA; Flies DB; Liu D; Dong H; Sica GL; Zhu G; Tamada K; Chen L
    Nat Immunol; 2001 Mar; 2(3):269-74. PubMed ID: 11224528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells.
    Marshall KW; Marks JD
    J Immunother; 2001; 24(1):27-36. PubMed ID: 11211146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirecting effector T cells through their IL-2 receptors.
    Lustgarten J; Marks J; Sherman LA
    J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.
    Tsang KY; Zhu M; Even J; Gulley J; Arlen P; Schlom J
    Cancer Res; 2001 Oct; 61(20):7568-76. PubMed ID: 11606396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.